Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
arcticnovartis

  • 33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1

  • Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1
/by

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
arcticnovartis

  • 33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1

  • Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients1
/by

Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Novartis announces commencement of tender offer to acquire Regulus Therapeutics
arcticnovartis

Basel, May 27, 2025 – Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one co

/by

Why advocating for your MS is so important

Why advocating for your MS is so important
hajdola1

/by

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis

  • NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients
  • Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settings
  • Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5
/by

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis

  • NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients
  • Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settings
  • Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5
/by

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis

  • NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients
  • Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settings
  • Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5
/by

Vas Narasimhan named to 2025 TIME100 Health list

Vas Narasimhan named to 2025 TIME100 Health list
angilma1

/by

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
arcticnovartis

  • There is currently no evidence-based treatment for the smallest babies with malaria
  • The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic differences in babies under 5 kg
  • The CALINA trial indicated that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review

Basel, April 24, 2024 – Novartis and Medicines for Malaria Venture (MMV) announce positive data from the

/by